tolazamide has been researched along with Obesity in 8 studies
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.
tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin requirements, C-peptide levels, and serum lipids have been assessed in 12 obese, insulin-requiring (greater than 60 U/day) patients with type II diabetes mellitus, in a randomized crossover fashion with two treatment regimens: NPH alone and combined NPH and tolazamide, over a period of 3 months each, with maintenance of weight and glycemic control (HgA1, 2hpp and mean 24h glucose profile) at comparable levels." | 9.06 | Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. ( Kitabchi, AE; Lawson-Grant, V; Radparvar, A; Soria, AG, 1987) |
| "Insulin requirements, C-peptide levels, and serum lipids have been assessed in 12 obese, insulin-requiring (greater than 60 U/day) patients with type II diabetes mellitus, in a randomized crossover fashion with two treatment regimens: NPH alone and combined NPH and tolazamide, over a period of 3 months each, with maintenance of weight and glycemic control (HgA1, 2hpp and mean 24h glucose profile) at comparable levels." | 5.06 | Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. ( Kitabchi, AE; Lawson-Grant, V; Radparvar, A; Soria, AG, 1987) |
| "Glyburide and other sulfonylureas consistently enhance receptor binding in cells from patients with non-insulin-dependent diabetes mellitus, whereas no effects and mixed effects have been demonstrated in cells from patients with insulin-dependent diabetes mellitus and in normal cells, respectively." | 3.67 | Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects. ( Gavin, JR, 1985) |
| "We compared 24 obese Pima Indians with NIDDM to 24 Pima Indians with normal glucose tolerance to determine whether resting metabolic rate changes may be an additional factor influencing the weight shifts." | 1.27 | Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. ( Bogardus, C; Howard, BV; Lillioja, S; Mott, D; Taskinen, MR; Zawadzki, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| BRESSLER, R | 1 |
| KATZ, R | 1 |
| Skillman, CA | 1 |
| Fletcher, HP | 1 |
| Kitabchi, AE | 1 |
| Soria, AG | 1 |
| Radparvar, A | 1 |
| Lawson-Grant, V | 1 |
| Gavin, JR | 1 |
| Bogardus, C | 1 |
| Taskinen, MR | 1 |
| Zawadzki, J | 1 |
| Lillioja, S | 1 |
| Mott, D | 1 |
| Howard, BV | 1 |
| Stowers, JM | 1 |
| Jackson, WP | 1 |
| Bricker, LA | 1 |
| Mintz, DH | 1 |
3 reviews available for tolazamide and Obesity
| Article | Year |
|---|---|
Oral treatment in diabetes.
Topics: Acetohexamide; Acidosis; Administration, Oral; Animals; Biguanides; Cardiovascular Diseases; Chlorpr | 1972 |
Oral sulphonylureas in the management of diabetes.
Topics: Acetohexamide; Chlorpropamide; Cyclohexanes; Diabetes Mellitus; Endocrine Glands; Glucose Tolerance | 1971 |
Insulin-independent diabetes mellitus.
Topics: Acetohexamide; Adult; Age Factors; Aged; Basement Membrane; Capillaries; Carbohydrate Metabolism, In | 1971 |
1 trial available for tolazamide and Obesity
| Article | Year |
|---|---|
Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dr | 1987 |
4 other studies available for tolazamide and Obesity
| Article | Year |
|---|---|
EVALUATION OF TOLAZAMIDE IN THE TREATMENT OF DIABETES MELLITUS.
Topics: Cholesterol; Diabetes Mellitus; Drug Therapy; Geriatrics; Hypoglycemic Agents; Obesity; Pharmacology | 1965 |
2-Deoxyglucose tissue levels and insulin levels following tolazamide dosing in normal and obese mice.
Topics: Adipose Tissue; Animals; Deoxy Sugars; Deoxyglucose; Insulin; Insulin Resistance; Male; Mice; Mice, | 1986 |
Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects.
Topics: Adipose Tissue; Animals; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mel | 1985 |
Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy.
Topics: Adolescent; Adult; Blood Glucose; Calorimetry; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy | 1986 |